Profile data is unavailable for this security.
About the company
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.
- Revenue in USD (TTM)0.00
- Net income in USD-7.61m
- Incorporated2014
- Employees10.00
- LocationMonopar Therapeutics Inc1000 Skokie Blvd Ste 350WILMETTE 60091-1146United StatesUSA
- Phone+1 (847) 388-0349
- Fax+1 (302) 655-5049
- Websitehttps://www.monopartx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allarity Therapeutics Inc | 0.00 | -20.94m | 10.13m | 5.00 | -- | -- | -- | -- | -599.34 | -599.34 | 0.00 | -18.88 | 0.00 | -- | -- | 0.00 | -100.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.02 | -- | -- | -- |
| Eterna Therapeutics Inc | 115.00k | -22.92m | 10.33m | 8.00 | -- | -- | -- | 89.86 | -4.25 | -4.25 | 0.0214 | -0.6307 | 0.0036 | -- | 0.2305 | 14,375.00 | -70.71 | -169.05 | -88.77 | -223.00 | -114.78 | -- | -19,912.17 | -682.61 | -- | -15.55 | 1.64 | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
| Kintara Therapeutics Inc | 0.00 | -9.51m | 10.39m | 2.00 | -- | -- | -- | -- | -4.08 | -4.08 | 0.00 | 0.1071 | 0.00 | -- | -- | 0.00 | -131.55 | -220.94 | -185.60 | -329.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 40.24 | -- | 78.93 | -- |
| 22nd Century Group Inc | 29.75m | -62.89m | 10.53m | 64.00 | -- | -- | -- | 0.354 | -40.02 | -97.93 | 17.94 | -3.23 | 0.40 | 5.90 | 5.47 | 464,796.90 | -66.29 | -46.78 | -92.49 | -54.18 | -33.09 | -2.11 | -165.75 | -107.95 | 0.4284 | -3.67 | 4.76 | -- | -20.49 | 4.03 | -76.94 | -- | 53.60 | -- |
| Protext Mobility Inc | 750.00 | -2.21m | 10.55m | 4.00 | -- | -- | -- | 14,065.96 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
| Moleculin Biotech Inc | 0.00 | -26.82m | 10.59m | 18.00 | -- | 0.4904 | -- | -- | -12.94 | -12.94 | 0.00 | 9.34 | 0.00 | -- | -- | 0.00 | -65.50 | -46.84 | -75.07 | -51.49 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.56 | -- | -21.54 | -- |
| Shineco Inc | 5.62m | -14.34m | 10.64m | 87.00 | -- | 0.2955 | -- | 1.89 | -3.98 | -2.32 | 1.36 | 5.58 | 0.0664 | 0.48 | 1.45 | 64,633.68 | -19.79 | -12.77 | -38.28 | -16.84 | 12.77 | 25.88 | -298.09 | -102.06 | 0.4842 | -8.14 | 0.3908 | -- | -- | -58.35 | -33.86 | -- | -- | -- |
| Psyence Biomedical Ltd | 0.00 | 1.52m | 10.75m | -- | -- | -- | 7.10 | -- | -0.0442 | -0.0442 | 0.00 | -0.3979 | 0.00 | -- | -- | -- | 1.13 | -- | 1.20 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.63 | -- | -- | -- |
| Monopar Therapeutics Inc | 0.00 | -7.61m | 10.84m | 10.00 | -- | 1.45 | -- | -- | -0.5289 | -0.5289 | 0.00 | 0.4277 | 0.00 | -- | -- | 0.00 | -73.36 | -54.07 | -92.67 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
| Galera Therapeutics Inc | 0.00 | -45.75m | 11.10m | 7.00 | -- | -- | -- | -- | -0.9971 | -0.9971 | 0.00 | -2.48 | 0.00 | -- | -- | 0.00 | -115.30 | -83.69 | -142.79 | -97.54 | -- | -- | -- | -- | -- | -6.49 | 9.23 | -- | -- | -- | 5.05 | -- | -29.84 | -- |
| Medical Marijuana Inc | -100.00bn | -100.00bn | 11.37m | -- | -- | 0.1052 | -- | -- | -- | -- | -- | 0.019 | -- | -- | -- | -- | -- | -22.66 | -- | -23.11 | -- | 70.58 | -- | -145.52 | 1.79 | -- | 0.0479 | -- | 26.30 | 39.07 | 141.59 | -- | -0.016 | -- |
| Vaxxinity Inc | 0.00 | -56.94m | 11.41m | 57.00 | -- | 0.8507 | -- | -- | -0.4499 | -0.4499 | 0.00 | 0.1058 | 0.00 | -- | -- | 0.00 | -75.56 | -- | -111.46 | -- | -- | -- | -- | -- | -- | -- | 0.5308 | -- | -- | -- | 24.31 | -- | -- | -- |
| GlucoTrack Inc | 0.00 | -8.74m | 11.56m | 6.00 | -- | 30.03 | -- | -- | -1.87 | -1.87 | 0.00 | 0.0703 | 0.00 | -- | -- | 0.00 | -520.58 | -94.01 | -2,110.63 | -142.35 | -- | -- | -- | -10,447.96 | -- | -- | 0.3415 | -- | -- | -- | -60.02 | -- | -- | -- |
Data as of May 28 2024. Currency figures normalised to Monopar Therapeutics Inc's reporting currency: US Dollar USD
2.23%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Millennium Management LLCas of 31 Mar 2024 | 192.38k | 1.10% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 45.17k | 0.26% |
| Geode Capital Management LLCas of 31 Mar 2024 | 41.20k | 0.24% |
| HRT Financial LLCas of 31 Mar 2024 | 32.11k | 0.18% |
| Gerber LLCas of 31 Mar 2024 | 28.01k | 0.16% |
| Virtu Americas LLCas of 31 Mar 2024 | 23.83k | 0.14% |
| Rappaport Reiches Capital Management LLCas of 31 Mar 2024 | 10.70k | 0.06% |
| Tower Research Capital LLCas of 31 Mar 2024 | 7.86k | 0.05% |
| Strategic Advisers LLCas of 31 Mar 2024 | 5.50k | 0.03% |
| NewEdge Advisors LLCas of 31 Mar 2024 | 3.00k | 0.02% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
